

Gastric - 2000µg/ml in 0.01N HCl
Intestinal - 1000µg/ml in 0.5wt% SIF in PBS pH 6.5
25% A: HPMCAS-M SD
50% A: HPMCAS-M SD
25% A: HPMC SD
Compound 1
(µg/mL)
1000
800
600
400
200
0
-30
0
30
60
90
1200
Time (min)

FIG. 1



Compound I µgA/mL
1000
900
800
700
600
500
400
300
200
100
0
983
2
864
3
138
329
529
142
845
18
157
API
2.5%A:HPMC
2.5%:HPMCAS-M
50%:HPMCAS-M
Undissolved Solids
Drug+Polymer Colloids
Free Drug

FIG. 2



G: 2000µgA/mL in 0.01N HCl
IB: 1000µgA/mL in 0.5wt% SIF in 1xPBS
25%A HPMCAS-M SDD
33%A HPMCAS-L SDD
30/60/10 API/PVPVA/TPGS HME
Crystalline API
Compound I (µg/mL)
Time (min)

FIG. 3



Plasma concentration[ng/ml]
100000
10000
1000
100
10
0
4
8
12
16
20
24
Time(hr)
10% TPGS
25% HPMCAS
50% HPMCAS
25% HPMC

FIG. 4A



AUC (h*ng/mL)
250000
200000
150000
100000
50000
0
10% TPGS
25% HPMCAS
50% HPMCAS
25% HPMC

FIG. 4B



SDDs Dog PK Studies; 10mg/kg; D0 = 16
250
200
150
100
50
mean AUC 0-last (hr µg/ml)
Oral Solution
25% HPMCAS-M
33.3% HPMCAS-L
50% HPMCAS-M
25% HPMC
0
100
200
300
400
500
600
Colloids present at 90min in non sink disso (µg/ml)

FIG. 4C



AUClast, hr·ng/mL
30000
25000
20000
15000
10000
5000
0
0
1
2
3
4
SD
PIB
Tablet
1 = SD
2 = PIB
3 = Tablet

FIG. 5A



Cmax, ng/mL
20000
15000
10000
5000
0
0
1
2
3
4
SD
PIB
Tablet
1 = SD
2 = PIB
3 = Tablet

FIG. 5B



20000
15000
10000
5000
0
AUCinf(hr·ng/mL)
PiB
SD suspension
Tablet
Dosage

FIG. 5C